| Title: | Screening for ovarian cancer in women with varying levels of risk, using annual tests, results in high recall for repeat screening tests. |
| Authors: | Nobbenhuis, Marielle AE Bancroft, Elizabeth Moskovic, Eleanor Lennard, Fiona Pharoah, Paul Jacobs, Ian Ward, Ann Barton, Desmond PJ Ind, Thomas EJ Shepherd, John H Bridges, Jane E Gore, Martin Haracopos, Chris Shanley, Susan Ardern-Jones, Audrey Thomas, Sarah Eeles, Rosalind A |
| Issue Date: | 23-Nov-2011 |
| Abstract: | Abstract Background We assessed ovarian cancer screening outcomes in women with a positive family history of ovarian cancer divided into a low-, moderate- or high-risk group for development of ovarian cancer. Methods 545 women with a positive family history of ovarian cancer referred to the Ovarian Screening Service at the Royal Marsden Hospital, London from January 2000- December 2008 were included. They were stratified into three risk-groups according to family history (high-, moderate- and low-risk) of developing ovarian cancer and offered annual serum CA 125 and transvaginal ultrasound screening. The high-risk group was offered genetic testing. Results The median age at entry was 44 years. The number of women in the high, moderate and low-risk groups was 397, 112, and 36, respectively. During 2266 women years of follow-up two ovarian cancer cases were found: one advanced stage at her fourth annual screening, and one early stage at prophylactic bilateral salpingo-oophorectomy (BSO). Prophylactic BSO was performed in 138 women (25.3%). Forty-three women had an abnormal CA125, resulting in 59 repeat tests. The re-call rate in the high, moderate and low-risk group was 14%, 3% and 6%. Equivocal transvaginal ultrasound results required 108 recalls in 71 women. The re-call rate in the high, moderate, and low-risk group was 25%, 6% and 17%. Conclusion No early stage ovarian cancer was picked up at annual screening and a significant number of re-calls for repeat screening tests was identified. |
| Description: | RIGHTS : This article is licensed under the BioMed Central licence at http://www.biomedcentral.com/about/license which is similar to the 'Creative Commons Attribution Licence'. In brief you may : copy, distribute, and display the work; make derivative works; or make commercial use of the work - under the following conditions: the original author must be given credit; for any reuse or distribution, it must be made clear to others what the license terms of this work are. |
| URI: | http://www.dspace.cam.ac.uk/handle/1810/240688 |
| Other Identifiers: | http://dx.doi.org/10.1186/1897-4287-9-11 |
| Appears in Collections: | Scholarly works - Oncology |
Files in This Item:
|
| Additional resources for this item |
|---|
| search for alternative versions in eresources@cambridge |
| retrieve citation metadata in EndNote format |
This item has been accessed 260 times.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

